Human vascular adhesion protein‐1 (VAP‐1) is a homodimeric 170‐kDa sialoglycoprotein that is expressed on the surface of endothelial cells and functions as a semicarbazide‐sensitive amine oxidase and as an adhesion molecule. Blockade of VAP‐1 has been shown to reduce leukocyte adhesion and transmigration in in vivo and in vitro models, suggesting that VAP‐1 is a potential target for anti‐inflammatory therapy. In this study we have constructed mouse‐human chimeric antibodies by genetic engineering in order to circumvent the potential problems involved in using murine antibodies in man. Our chimeric anti‐VAP‐1 antibodies, which were designed to lack Fc‐dependent effector functions, bound specifically to cell surface‐expressed recombinant human VAP‐1 and recognized VAP‐1 in different cell types in tonsil. Furthermore, the chimeric antibodies prevented leukocyte adhesion and transmigration in vitro and in vivo. Hence, these chimeric antibodies have the potential to be used as a new anti‐inflammatory therapy.
- Chimeric antibody
- Cell adhesion
- Vascular adhesion protein-1
- Fc receptor
Kirton, C. M., Laukkanen, M-L., Nieminen, A., Merinen, M., Stolen, C. M., Armour, K., Smith, D. J., Salmi, M., Jalkanen, S., & Clark, M. R. (2005). Function-blocking antibodies to human vascular adhesion protein-1: A potential anti-inflammatory therapy. European Journal of Immunology, 35(11), 3119 - 3130. https://doi.org/10.1002/eji.200535300